Share Price, page-10786

True, which will be sufficient. It would be nice if the company continued to do them because I like knowing how much cashflow we're generating. It doesn't really matter because we have plenty of cash but wonder the impact of trial completion on our R&D spend, or if it would be stable or increase slightly with activities in preparation for Phase 3. Some of this R&D spend is tax deductable so a high % of our expenses being R&D is very healthy.

In Q1 we generated 2.7m interest which exceeded our staff and admin/corporate (SG&A) costs of roughly 2m. I find this fact baffling compared to other ASX listed biotechnology or device companies, regardless of their stage of development that this doesn't get discussed as much. If am also curious if we can continue that, whereby our cash balance (and interest) income grows faster compared to those expenses. This will shift if we go to P3 under multiple conditions but it strengthens our position in the lead-up.